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Examination of potential novel biochemical factors in relation
to prostate cancer incidence and mortality in UK Biobank
Aurora Perez-Cornago 1, Georgina K. Fensom1, Colm Andrews1, Eleanor L. Watts1, Naomi E. Allen2, Richard M. Martin 3,4,5,
Mieke Van Hemelrijck6,7, Timothy J. Key1 and Ruth C. Travis1
BACKGROUND: Although prostate cancer is a leading cause of cancer death, its aetiology is not well understood. We aimed to
identify novel biochemical factors for prostate cancer incidence and mortality in UK Biobank.
METHODS: A range of cardiovascular, bone, joint, diabetes, renal and liver-related biomarkers were measured in baseline blood
samples collected from up to 211,754 men at recruitment and in a subsample 5 years later. Participants were followed-up via
linkage to health administrative datasets to identify prostate cancer cases. Hazard ratios (HRs) and 95% confidence intervals were
calculated using multivariable-adjusted Cox regression corrected for regression dilution bias. Multiple testing was accounted for by
using a false discovery rate controlling procedure.
RESULTS: After an average follow-up of 6.9 years, 5763 prostate cancer cases and 331 prostate cancer deaths were ascertained.
Prostate cancer incidence was positively associated with circulating vitamin D, urea and phosphate concentrations and inversely
associated with glucose, total protein and aspartate aminotransferase. Phosphate and cystatin-C were the only biomarkers
positively and inversely, respectively, associated with risk in analyses excluding the first 4 years of follow-up. There was little
evidence of associations with prostate cancer death.
CONCLUSION: We found novel associations of several biomarkers with prostate cancer incidence. Future research will examine
associations by tumour characteristics.
British Journal of Cancer (2020) 123:1808–1817; https://doi.org/10.1038/s41416-020-01081-3
BACKGROUND
Prostate cancer is the second most commonly diagnosed cancer
in men worldwide after lung cancer and is a leading cause of
cancer death.1 However, its well-established risk factors age,
ethnicity family history and other genetic factors are not
modifiable.2,3 There is evidence that higher circulating insulin-
like growth factor-I (IGF-I) concentrations are related to higher
overall prostate cancer risk,4,5 and obesity has been associated
with a higher risk of aggressive disease.6 Moreover, men with low
free testosterone concentrations may have a lower risk of overall
prostate cancer.7 However, the aetiology of prostate cancer is not
well understood, and there is a need to identify novel risk factors
for the disease.
There is some evidence that some non-communicable diseases
are associated with prostate cancer risk. Men with diabetes or
kidney disease have a lower risk of being diagnosed with prostate
cancer,8,9 but it is unknown whether concentrations of common
biochemical factors related to other non-communicable diseases,
such as cardiovascular or liver disease, are also associated with
prostate cancer. Due to the high cost of measuring multiple
biomarkers in samples from an entire cohort, most previous
studies of potential biomarkers for prostate cancer risk have been
nested case-control studies of a small number of selected putative
cancer biomarkers.
The UK Biobank prospective cohort study is an important
resource for the study of cancer aetiology. UK Biobank has measured
concentrations of multiple biomarkers known to be related to
several non-communicable diseases (i.e. cardiovascular, bone and
joint, diabetes, renal and liver diseases) in blood and urine samples
from every participant in the cohort. This provides a unique
opportunity to investigate a wide range of biomarkers, including
biomarkers that have not previously been studied in relation to
prostate cancer risk. We report here the first results from this cohort
on the association of concentrations of blood and urine biomarkers
known to be related to other non-communicable diseases with
prostate cancer incidence and mortality in a large British cohort.
METHODS
Study design and population
UK Biobank is a prospective study of >500,000 people (aged 40–69
years, including 229,000 men) designed to be a resource for
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research into the causes of disease in middle and old age. The study
protocol and information about data access are available online
(http://www.ukbiobank.ac.uk/wp-content/uploads/2011/11/UK-
Biobank-Protocol.pdf) and elsewhere.10 All the covariates were
measured at the same time as the biological samples were collected.
Briefly, persons who lived within reasonable traveling distance
(∼25 km) of 1 of the 22 assessment canters across England, Wales
and Scotland were identified from National Health Service (NHS)
registers and invited to participate in the study between 2006–2010,
resulting in a participation rate of 5.5%.11 At recruitment,
participants provided detailed information on a range of socio-
demographic, physical, lifestyle and health-related factors via self-
completed touch-screen questionnaires and a computer assisted
personal interview.11 Anthropometric measurements (standing
height, weight, waist and hip circumferences) were taken by trained
research clinic staff at the assessment centre, while body mass index
[BMI] and percentage body fat were assessed through bioimpe-
dance measures.12 A total of 211,754 men were included in these
analyses; a study flowchart showing all the exclusions can be found
in Supplemental Fig. 1.
Blood and urine collection and laboratory analysis
Blood and a mid-flow urine sample (both non-fasting) were
collected at recruitment from 99.7% and 96% of participants,
respectively. Repeat blood and urine samples were collected in
~9000 men between August 2012 and June 2013 at the UK Biobank
Co-ordinating Centre in Stockport; participants who lived within a
35 km radius were invited to attend, with an overall response rate of
21%.13,14 Blood and urine samples were shipped to the central
processing laboratory at 4 °C prior to serum preparation, aliquoting
and cryopreservation in a central working archive.15,16
For the current analysis, we have included 28 biochemistry
markers (cardiovascular, bone, joint, diabetes, renal and liver-
related biomarkers, please see Table 1 for the full biomarker list)
that were measured in 229,000 men. UK Biobank did not release
data on biomarkers outside of the limit of detection for each
individual biomarker; therefore, extreme outliers are already not
included in the dataset. Details about assay methods and quality
control procedures are available online (https://biobank.ndph.ox.
ac.uk/showcase/showcase/docs/serum_biochemistry.pdf and
http://biobank.ctsu.ox.ac.uk/crystal/crystal/docs/urine_assay.pdf).
Ascertainment of prostate cancer incidence and mortality
For prostate cancer incidence, the endpoint was first diagnosis of
prostate cancer (International Classification of Diseases Tenth
revision codes: C6117) or death from prostate cancer (prostate
cancer mentioned on the death certificate), whichever was first. Men
were followed-up for cancer incidence until the censoring dates (31
March 2016 in England and Wales and 31 October 2015 in Scotland).
For analyses of prostate cancer mortality, the endpoint was
prostate cancer as the underlying cause of death recorded on the
death certificate and men were followed-up until 31 January 2018
for England and Wales and 30 November 2016 for Scotland.
Cancer incidence and mortality data were provided by the NHS
Digital for England and Wales and by the NHS Central Register and
Information and Statistics Division for Scotland. Person-years were
calculated from the date of recruitment to the date of cancer
registration (first malignant neoplasm, except non-melanoma skin
cancer (ICD-10 C44)), death date lost to follow-up or the censoring
date, whichever occurred first.
Statistical analysis
Logarithmically transformed concentrations of the biochemistry
markers were used for all analyses to approximate a normal
distribution. Cox proportional hazards models were used to calculate
hazard ratios (HRs) and 95% confidence intervals (CIs) for prostate
cancer incidence and death, using age as the underlying time
Table 1. Baseline characteristics and biochemical data of all men and
men who developed prostate cancer in UK Biobank.
All men (N= 211,754) Men who developed
prostate cancer (N= 5763)
Sociodemographic
Age at recruitment (years), mean (SD) 56.53 (8.20) 62.16 (5.26)
<45 10.76 (23,377) 0.42 (25)
45–49 13.10 (28,456) 2.25 (133)
50–54 14.72 (31,961) 6.86 (406)
55–59 17.63 (38,298) 15.17 (898)
60–64 23.94 (51,998) 37.66 (2229)
≥65 19.85 (43,109) 37.63 (2227)
Most deprived quintile, % (n) 19.76 (41,787) 15.60 (898)
Black ethnicity, % (n) 1.49 (3139) 2.09 (120)
Not in paid/self-employment, % (n) 38.58 (81,705) 57.02 (3286)
Living with partner, % (n) 92.93 (161,896) 95.39 (4573)
Anthropometric, mean (SD)
Height (cm) 175.64 (6.84) 175.10 (6.70)
Body fat (%) 25.24 (5.79) 25.42 (5.47)
BMI (kg/m2) 27.84 (4.24) 27.53 (3.79)
Lifestyle, % (n)
Current cigarette smokers 12.46 (26,225) 9.23 (529)
Drinking alcohol ≥20 g per day 43.54 (91,706) 42.55 (2443)
Low physical activity (0–10 METs
per week)
28.40 (58,145) 27.23 (1520)
Health history, % (n)
Hypertension 52.22 (110,509) 59.05 (3401)
Diabetes 6.88 (14,489) 5.88 (338)
Biomarkers, mean (SD)
Cardiovascular-related
Cholesterol, mmol/L 5.48 (1.13) 5.42 (1.11)
LDL-cholesterol, mmol/L 3.48 (0.86) 3.43 (0.85)
HDL-cholesterol, mmol/L 1.28 (0.31) 1.30 (0.32)
Triglycerides, mmol/L 1.98 (1.15) 1.87 (1.00)
Apolipoprotein A1, g/L 1.43 (0.23) 1.45 (0.23)
Apolipoprotein B, g/L 1.03 (0.24) 1.01 (0.23)
C-reactive protein, mg/L 2.43 (4.25) 2.37 (3.91)
Lipoprotein (a), nmol/L 43.82 (48.98) 45.41 (50.02)
Bone and joint-related
Vitamin D, nmol/L 48.49 (21.21) 51.74 (21.04)
Alkaline phosphatase, U/L 81.94 (24.16) 81.97 (29.37)
Calcium, mmol/L 2.37 (0.09) 2.37 (0.09)
Diabetes-related
HbA1c, mmol/mol 36.49 (7.60) 36.58 (6.64)
Glucose, mmol/L 5.19 (1.41) 5.15 (1.22)
Renal-related
Cystatin-C, mg/L 0.94 (0.18) 0.96 (0.17)
Creatinine, umol/L 81.58 (18.69) 82.83 (19.90)
Total protein, g/L 72.64 (4.08) 72.05 (4.05)
Urea, mmol/L 5.60 (1.44) 5.83 (1.50)
Phosphate, mmol/L 1.12 (0.16) 1.12 (0.16)
Urate, umol/L 354.41 (71.59) 352.48 (69.76)
Creatinine (Urine), micromole/L 10.90 (6.10) 10.58 (5.79)
Microalbumin (Urine), mg/L 11.02 (24.76) 11.25 (24.48)
Potassium/creatinine ratio 6.98 (3.87) 7.22 (2.84)
Sodium/creatinine ratio 9.67 (5.64) 9.41 (5.19)
Liver-related
Albumin, g/L 45.54 (2.61) 45.15 (2.54)
Direct bilirubin, umol/L 2.01 (0.94) 2.04 (0.88)
Total bilirubin, umol/L 10.31 (4.92) 10.44 (5.00)
Gamma glutamyltransferase, U/L 45.66 (48.30) 43.64 (39.22)
ALT, U/L 27.52 (15.28) 25.47 (13.78)
AST, U/L 28.25 (11.39) 27.48 (12.45)
ALT alanine aminotransferase, ApoA1 apolipoprotein A1, ApoB apolipopro-
tein B, AST aspartate aminotransferase, BMI body mass index, HbA1c
haemoglobin A1c, HDL high-density lipoprotein, LDL-cholesterol low-
density lipoperotein cholesterol, METs metabolic equivalents, SD standard
deviation.
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variable. Men were categorised into fifths (for incident analyses) and
thirds (for death analyses, due to the more limited number of
events) of biomarker concentrations based on the distribution in the
cohort. We also modelled HRs per SD higher concentrations. The
minimally adjusted models were stratified by geographical region of
recruitment (ten UK regions) and age (<45, 45–49, 50–54, 55–59,
60–64 and ≥65 years) at recruitment. The fully adjusted model was
further adjusted for Townsend deprivation score (fifths, unknown
[0.1%]), ethnic group (white, mixed background, Asian, black, other
and unknown [0.7%]), height (<170, 170–174.9, 175–179.9 and ≥180
cm and unknown [0.6%]), lives with a wife or partner (no, yes), body
mass index (BMI) (<25, 25–<29.9, 30–34.9 and ≥35 kg/m2 and
unknown [0.6%]), cigarette smoking (never, former, current 1–<15
cigarettes per day, current ≥15 cigarettes per day, current but
number of cigarettes per day unknown and smoking status
unknown [0.7%]), physical activity (low [0–9.9 METs/week], moderate
[10–49.9 METs/week] and high [≥50 METs/week], unknown [3.7%]),
alcohol consumption (non-drinkers, <1–9.9, 10–19.9 and ≥20 g
ethanol/day, unknown [0.6%]) and diabetes (no, yes, and unknown
[0.6%]). For the vitamin D analyses, we further adjusted the fully
adjusted model by month of recruitment to allow for the influence
of month of blood draw on circulating concentrations. Categories of
the adjustment covariates were defined a priori based on previous
analyses by our group using UK Biobank data.8 To check for violation
of the proportional hazards assumption we examined time-varying
covariates and Schoenfeld residuals. This check did not indicate any
such violation.
Measurement error and within-person variability when using
single biomarker measurements lead to under-estimation (regres-
sion dilution bias) of potential associations between biomarker
concentrations and prostate cancer risk.18 Repeated biomarker
measures were available from a subsample of ~9000 men who
had provided a second blood sample ~4–5 years after recruitment,
and these were used to correct risk analyses for regression dilution
bias using the McMahon–Peto method.19 In MacMahon’s method,
individuals are grouped into fifths according to their first
biomarker measurement, and the mean of the biomarker is
calculated for each group at each repeat. The MacMahon’s
regression dilution ration (RDR) is the ratio of the range of means
at the repeat to the range of means at the first measurement.
Sensitivity analyses to reduce reverse causality were performed
by repeating the analyses after excluding the first 4 years of
follow-up; due to the relatively small number of deaths and
limited statistical power, this sensitivity analysis was not
performed for prostate cancer death. We also restricted analyses
to those biomarkers measured using aliquot 1, which was the vast
majority (~88% of the samples), in order to assess whether
the inadvertent dilution of some aliquots had an impact on
the associations.20 Finally, we restricted analyses to men aged
≥50 years to exclude those with very prostate cancer risk.
All analyses were performed using Stata version 14.1 (Stata
Corporation, College Station, TX, USA), all tests of significance were
two-sided, and to account for multiple testing the false discovery




During the follow-up period (mean 6.9 years, SD: 1.4 for incidence;
and 8.7 years, SD: 1.2 for mortality), 5968 men were diagnosed
with prostate cancer and there were 331 prostate cancer deaths.
Table 1 shows the characteristics of the study participants at
baseline, including means and SDs for baseline biomarker
measurements. Among all participants, the mean BMI was 27.8
kg/m2, 13% reported that they were current cigarette smokers,
43.5% reported drinking at least 20 g of alcohol per day and 28.7%
of men reported being physically inactive. The mean age at
diagnosis was 66 years (SD, 5.4 years). Regression dilution ratios,
which measure within-person variability, are reported in Supple-
mentary Table 1, and ranged from 0.21 to 1.03, with an average
of 0.62.
The associations of concentrations of blood and urine biomar-
kers with prostate cancer incidence, corrected for regression
dilution bias, are reported in Figs. 1–3, and associations without
correction for regression dilution bias are shown in Supplementary
Tables 2, 3, 4 and 5, while both uncorrected and corrected HRs for
1-SD higher circulating concentrations of each biomarker are
shown in Supplementary Table 1. The associations were generally
slightly greater in magnitude after adjustment for regression
dilution bias (see Supplementary Table 1); the HRs and (95% CIs)
below reported in the text below are the corrected results.
Cardiovascular-related biomarkers
Figure 1 (and Supplementary table 2) shows that cardiovascular-
related biomarkers [total cholesterol, low-density lipoprotein–
cholesterol (LDL-c), high-density lipoprotein–cholesterol (HDL-c),
triglycerides (TG), apolipoprotein A-I (ApoA-I), apolipoprotein B
(ApoB), C-reactive protein (CRP) and lipoprotein a] were not related
to prostate cancer diagnosis or mortality.
Bone- and joint-related biomarkers
Higher circulating vitamin D concentrations were associated with
an elevated risk of prostate cancer (HR per 1 SD increase 1.11, 95%
CI 1.05–1.17, P trend= 0.0004) (Fig. 1 and Supplementary table 3).
There was little evidence that concentrations of the other bone-
and joint-related biomarkers were associated with prostate cancer
incidence or death (Fig. 1 and Table 2).
Diabetes-related biomarkers
Men with higher circulating glycated haemoglobin (HbA1c)
concentration had a higher risk of dying from prostate cancer
(HR per 1 SD increase 1.19, 1.02–1.39, P trend= 0.024; Table 2), but
this association did not survive correction for multiple testing.
Higher glucose concentration was associated with a lower
prostate cancer risk (0.90, 0.84–0.97, P trend= 0.0082; Fig. 1),
but was not associated with prostate cancer mortality.
Renal-related biomarkers
Men with higher circulating total protein concentrations had a
lower prostate cancer risk (HR per 1 SD increase 0.88, 0.84–0.93,
P trend= 0.0001; Fig. 2). Circulating urea and phosphate concen-
trations were associated with an increased prostate cancer risk
(1.07, 1.02–1.12, P trend= 0.0036; and 1.13, 1.05–1.22, P trend=
0.0006, respectively). Renal-related biomarkers were not associated
with prostate cancer mortality.
Liver-related biomarkers
Higher circulating aspartate aminotransferase (AST) concentration
was associated with a lower prostate cancer risk (HR per 1 SD
increase 0.90, 0.85–0.94, P trend ≤ 0.0001; Fig. 3). We also found
that men with higher circulating total bilirubin concentration had
a lower risk of prostate cancer death (0.83, 0.71–0.98, P trend=
0.028; Table 2), although this association did not survive correction
for multiple testing. The other liver-related biomarkers were not
related to prostate cancer diagnosis or death.
Sensitivity analyses
After excluding the first 4 years of follow-up the 95% confidence
intervals were wider and only cystatin-C and phosphate were
associated with prostate cancer risk after controlling for multiple
testing (HR per 1 SD increase 0.93, 0.89–0.97; and 1.07, 1.05–1.29,
respectively; Table 3).
The associations reported above did not vary when analyses
were restricted to blood samples from aliquot 1 (Supplementary
Table 6) or to men aged ≥50 years (Supplementary Table 7).
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DISCUSSION
This large British prospective study with biomarkers measured in
the entire cohort found several associations with possible novel
biomarkers for prostate cancer incidence and mortality. The risk of
being diagnosed with prostate cancer was higher in those with
higher circulating concentrations of vitamin D, urea and
phosphate, while risk was lower in those with higher circulating
concentrations of glucose, total protein and AST. In analyses
excluding the first 4 years of follow-up, cystatin-C and phosphate
were associated with prostate cancer risk. After correction for
HR per 1-SD (95% CI) higher
concentration: 1.00 (0.96–1.04) 1.01 (0.97 – 1.05) 1.00 (0.96 – 1.03) 0.96 (0.91 – 1.01)
0.98 (0.94 – 1.02) 1.01 (0.96 – 1.05) 0.97 (0.91 – 1.02) 1.02 (0.99 – 1.05)
1.11 (1.05 – 1.17) 0.99 (0.96 – 1.02) 1.02 (0.96 – 1.09)























































































































































































































































































30 35 40 45 50 55 60 65 70
Vitamin D nmol/L
32 34 36 38 40 42 44 46
HbA1c mmol/mol
4.6 4.8 5 5.2 5.4 5.6 5.8 6
Glucose mmol/L
60 2.34 2.36 2.38 2.4 2.42 2.44 2.4670 80 90 100 110
Alkaline phosphatase U/L Calcium mmol/L
ApoB g/L C-reactive protein mg/L Lipoprotein (a) nmol/L
HDL-Cholesterol mmol/L Triglycerides mmol/L
6 6.5 2.5 1 1.2 1.4 1.6 1.8 1 1.5 2 2.5 33 3.5 4 4.5
Direct low density lipoprotein mmol/L
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Table 2. Hazard ratios (95% CI) for prostate cancer death by thirds (uncorrected for RDB) and one standard deviation increase (corrected for RDB) in
each biomarker in UK Biobank.
Biomarker Cases/non-
cases
Thirds P trend HR per 1-SD (95% CI) higher
concentrations
1. HR (95% CI) 2. HR (95% CI) 3. HR (95% CI) Corrected for RDB
Cardiovascular-related
Cholesterol 318/205,211 1 (Ref) 0.85 (0.65–1.13) 1.01 (0.77–1.33) 0.70 1.03 (0.87–1.23)
LDL-cholesterol 318/204,764 1 (Ref) 1.04 (0.80–1.36) 1.01 (0.76–1.33) 0.76 1.03 (0.87–1.22)
HDL-cholesterol 297/189,439 1 (Ref) 0.88 (0.65–1.17) 0.99 (0.73–1.33) 0.35 1.07 (0.93–1.23)
Triglycerides 318/204,986 1 (Ref) 0.94 (0.71–1.23) 1.05 (0.79–1.40) 0.87 0.98 (0.79–1.22)
ApoA1 296/189,166 1 (Ref) 0.82 (0.62–1.10) 0.90 (0.67–1.21) 0.43 1.07 (0.91–1.24)
ApoB 317/203,787 1 (Ref) 1.03 (0.79–1.35) 1.07 (0.81–1.42) 0.76 1.03 (0.86–1.23)
C-reactive protein 318/204,670 1 (Ref) 0.93 (0.69–1.24) 1.08 (0.81–1.43) 0.35 1.12 (0.89–1.40)
Lipoprotein (a) 240/163,568 1 (Ref) 1.14 (0.83–1.56) 1.12 (0.82–1.54) 0.68 1.03 (0.91–1.16)
Bone- and joint-related
Vitamin D 311/198,742 1 (Ref) 0.92 (0.69–1.22) 0.73 (0.53–1.00) 0.09 0.82 (0.65–1.03)
Alkaline phosphatase 317/205,206 1 (Ref) 1.06 (0.81–1.39) 0.96 (0.73–1.27) 0.12 1.11 (0.97–1.27)
Calcium 297/189,494 1 (Ref) 1.07 (0.81–1.41) 1.06 (0.80–1.41) 0.97 1.00 (0.76–1.31)
Diabetes-related
HbA1c 321/203,886 1 (Ref) 1.23 (0.91–1.67) 1.33 (0.99–1.80) 0.024 1.19 (1.02–1.39)
Glucose 296/189,316 1 (Ref) 1.00 (0.74–1.35) 1.26 (0.94–1.69) 0.085 1.28 (0.97–1.69)
Renal-related
Cystatin-C 318/205,189 1 (Ref) 1.30 (0.95–1.78) 1.20 (0.88–1.65) 0.79 1.02 (0.90–1.15)
Creatinine 318/205,099 1 (Ref) 0.87 (0.66–1.14) 0.86 (0.66–1.13) 0.35 0.93 (0.81–1.08)
Total protein 296/189,318 1 (Ref) 0.87 (0.66–1.17) 1.22 (0.93–1.61) 0.22 1.14 (0.92–1.41)
Urea 318/205,064 1 (Ref) 0.90 (0.67–1.20) 0.94 (0.71–1.23) 0.52 0.94 (0.78–1.13)
Phosphate 296/189,187 1 (Ref) 1.27 (0.96–1.67) 1.18 (0.88–1.58) 0.30 1.17 (0.87–1.58)
Urate 317/204,980 1 (Ref) 1.18 (0.90–1.55) 1.03 (0.77–1.37) 0.50 0.95 (0.82–1.10)
Microalbumin (Urine) 158/74,466 1 (Ref) 1.29 (0.88–1.89) 0.98 (0.65–1.48) 0.79 0.97 (0.77–1.22)
Potassium/creatinine ratio (urine) 330/210,966 1 (Ref) 0.98 (0.75–1.29) 0.91 (0.69–1.20) 0.89 0.97 (0.61–1.55)
Sodium/creatinine ratio (urine) 331/211,207 1 (Ref) 1.02 (0.79–1.33) 0.90 (0.69–1.18) 0.58 0.86 (0.52–1.44)
Liver-related
Albumin 297/189,561 1 (Ref) 1.07 (0.82–1.39) 1.05 (0.79–1.41) 0.91 1.01 (0.80–1.28)
Direct bilirubin 296/191,058 1 (Ref) 1.02 (0.78–1.33) 0.68 (0.51–0.92) 0.086 0.85 (0.71–1.02)
Total bilirubin 318/204,303 1 (Ref) 0.78 (0.60–1.02) 0.68 (0.52–0.90) 0.028 0.83 (0.71–0.98)
Gamma glutamyltransferase 318/205,082 1 (Ref) 1.14 (0.85–1.52) 1.52 (1.14–2.03) 0.077 1.14 (0.99–1.31)
ALT 318/205,038 1 (Ref) 0.87 (0.67–1.15) 1.15 (0.87–1.52) 0.75 1.04 (0.82–1.31)
AST 318/204,366 1 (Ref) 1.10 (0.84–1.43) 1.02 (0.78–1.35) 0.95 1.01 (0.82–1.23)
Cox regression analysis. HR are stratified by region and age at recruitment and adjusted for age (underlying time variable), Townsend deprivation score,
ethnicity, lives with a wife or partner, BMI, smoking, physical activity, alcohol consumption and diabetes. For vitamin D analyses, the model was further
adjusted for month of recruitment. Full details for each covariate are provided in the statistical section.
P values for trend from 1-SD higher concentrations analyses. None of the associations were statistically significant after correction for multiple testing.
ALT alanine aminotransferase, ApoA1 apolipoprotein A1, ApoB apolipoprotein B, AST aspartate aminotransferase, BMI body mass index, HbA1c haemoglobin
A1c, HDL high-density lipoprotein, HR hazard ratio, LDL-cholesterol low-density lipoperotein cholesterol, RDB regression dilution bias.
Fig. 1 Hazard ratio of incident prostate cancer by fifths of usual serum cardiovascular-, bone-, joint- and diabetes-related biomarker
concentrations in up to 205,529 men in UK Biobank. The hazard ratios above each plot are for 1-SD higher concentration of the biomarker
after correction for regression dilution bias. HRs are from Cox regression analyses stratified by region and age at recruitment and adjusted for
age (underlying time variable), Townsend deprivation score, ethnicity, lives with a wife or partner, BMI, smoking, physical activity, alcohol
consumption and diabetes. For vitamin D analyses, the model was further adjusted for month of recruitment. Full details for each covariate are
provided in the statistical section. The boxes represent the hazard ratios; the vertical lines represent the 95% CIs. The x-axis shows the mean
concentrations of the repeat biomarker measurement within each fifth. The numbers above the vertical lines are point estimates for hazard
ratios, and the numbers below are the number of prostate cancer diagnoses within each fifth. Multivariable-adjusted P values marked in
boldface were statistically significant after allowing for multiple testing. ApoA1 apolipoprotein A1, ApoB apolipoprotein B, BMI body mass
index, CI confidence intervals, HbA1c haemoglobin A1c, HDL high-density lipoprotein, HR hazard ratio, N number of prostate cancer cases.
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multiple testing, there was little evidence of associations with
prostate cancer death.
Cardiovascular-related biomarkers
Our results are consistent with findings from a meta-analysis of 14
prospective studies that do not support an association between
total cholesterol, LDL-c, HDL-c and TG concentrations and prostate
cancer risk.22 This is in-line with a previous Mendelian randomisa-
tion study that did not find an association of genetic variants for
these biomarkers with overall prostate cancer; however, that study
did find some evidence that higher LDL-c and TG levels increase
aggressive prostate cancer risk, and that a variant in HMGCR gene
HR per 1-SD (95% CI) higher
concentration: 0.96 (0.93 – 0.99)
1.02 (0.99 – 1.06) 0.88 (0.84 – 0.93)
1.07 (1.02 – 1.12) 1.13 (1.05 – 1.22) 0.96 (0.92 – 0.99)
1.07 (0.97 – 1.18) 0.95 (0.90 – 1.02) 0.96 (0.86 – 1.08)
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(that mimics the LDL lowering effect of statin drugs) reduces risk,
although there was some evidence of pleiotropy.23
There are limited published prospective data on ApoA-I and
ApoB in relation to prostate cancer risk. Our findings of no
association of ApoA-I concentrations with risk contrast to findings
from the one previous prospective analysis that found an inverse
association with overall prostate cancer,24 while our null findings
for ApoB are consistent with previous studies.24,25
In agreement with previous prospective studies,26–28 circulating
CRP concentrations were not related to prostate cancer incidence
or mortality in the current study.
Bone- and joint-related biomarkers
Higher circulating vitamin D concentrations were associated
with a higher risk of prostate cancer diagnosis in the current
study, which is consistent with a previous individual participant
meta-analysis of prospective studies;29 however, this association
was not significant after excluding the first 4 years of follow-up.
This finding may reflect detection bias; health-conscious men
may have a higher dietary intake of vitamin D and/or vitamin D
supplementation and higher sun exposure, and these men may
be more likely to have a prostate specific antigen (PSA) test or to
seek medical attention with early symptoms. Therefore, these
men may have a higher risk of being diagnosed with prostate
cancer.
We did not find an association between alkaline phosphatase or
calcium concentrations and prostate cancer incidence and
mortality. To the best of our knowledge, there is no previous
prospective evidence on the association between alkaline
phosphatase and prostate cancer risk, and results from previous
Fig. 2 Hazard ratio of incident prostate cancer by fifths of usual serum renal-related biomarker concentrations in up to 211,754 men in
UK Biobank. The hazard ratios above each plot are for 1-SD higher concentration of the biomarker after correction for regression dilution bias.
HRs are from Cox regression analyses stratified by region and age at recruitment and adjusted for age (underlying time variable), Townsend
deprivation score, ethnicity, lives with a wife or partner, BMI, smoking, physical activity, alcohol consumption and diabetes. Full details for each
covariate are provided in the statistical section. The boxes represent the hazard ratios; the vertical lines represent the 95% CIs. The x-axis
shows the mean concentrations of the repeat biomarker measurement within each fifth. The numbers above the vertical lines are point
estimates for hazard ratios, and the numbers below are the number of prostate cancer diagnoses within each fifth. Values marked in boldface
were statistically significant after allowing for multiple testing. Multivariable-adjusted P values marked in boldface were statistically significant
after allowing for multiple testing. BMI body mass index, CI confidence intervals, HR hazard ratio, N number of prostate cancer cases.
HR per 1-SD (95% CI) higher
concentration: 1.01 (0.96 – 1.07)
1.02 (0.98 – 1.07) 1.02 (0.98 – 1.06) 1.01 (0.98 – 1.05)
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Fig. 3 Hazard ratio of incident prostate cancer by fifths of usual serum liver-related biomarker concentrations in up to 204,621 men in
UK Biobank. The hazard ratios above each plot are for 1-SD higher concentration of the biomarker after correction for regression dilution bias.
HRs are from Cox regression analyses stratified by region and age at recruitment and adjusted for age (underlying time variable), Townsend
deprivation score, ethnicity, lives with a wife or partner, BMI, smoking, physical activity, alcohol consumption and diabetes. Full details for each
covariate are provided in the statistical section. The boxes represent the hazard ratios; the vertical lines represent the 95% CIs. The x-axis
shows the mean concentrations of the repeat biomarker measurement within each fifth. The numbers above the vertical lines are point
estimates for hazard ratios, and the numbers below are the number of prostate cancer diagnoses within each fifth. Values marked in boldface
were statistically significant after allowing for multiple testing. Multivariable-adjusted P values marked in boldface were statistically significant
after allowing for multiple testing. ALT alanine aminotransferase, AST aspartate aminotransferase, BMI body mass index, CI confidence
intervals, HR hazard ratio, N number of prostate cancer cases.
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prospective studies on circulating calcium concentration are not
conclusive.30–32
Diabetes-related biomarkers
In our study, higher glucose concentrations were related to a
lower prostate cancer risk, although there was a suggestion of a
positive association between circulating HbA1c concentration, a
marker of long-term poor glycaemic control, and risk of dying
from prostate cancer. However, the association with glucose was
not significant in after 4 years of follow-up and the association
with HbA1c did not survive correction for multiple testing. While
previous prospective evidence has shown an inverse association
between diabetes and prostate cancer risk,33 not many studies
have assessed the association of diabetes with prostate cancer
death. However, there is some prospective evidence that
hyperglycaemia may be associated with an increased risk of fatal
prostate cancer.34 Men with obesity are more likely to develop
type II diabetes, and our findings for diabetes-related biomarkers
in relation to prostate cancer risk are concordant with the current
evidence on adiposity and prostate cancer, which shows an
inverse association of adiposity with prostate cancer incidence but
a positive association with prostate cancer death.6
Table 3. Sensitivity analyses.
Biomarkers Time to diagnosis ≥ 4 years
Cases/non-cases HR (95% CI) P trend
Cardiovascular-related
Cholesterol 2713/193,818 1.07 (1.01–1.13) 0.030
LDL-cholesterol 2702/193,398 1.08 (1.02–1.15) 0.014
HDL-Cholesterol 2523/178,909 0.99 (0.94–1.04) 0.65
Triglycerides 2709/193,610 1.02 (0.95–1.10) 0.51
ApoA1 2520/178,658 0.98 (0.93–1.03) 0.44
ApoB 2702/192,454 1.08 (1.01–1.14) 0.019
C-reactive protein 2704/193,314 0.95 (0.87–1.03) 0.21
Lipoprotein (a) 2161/154,560 1.04 (1.00–1.09) 0.046
Bone- and joint-related
Vitamin D 2647/187,640 1.04 (0.96–1.13) 0.33
Alkaline phosphatase 2709/193,813 0.97 (0.93–1.02) 0.26
Calcium 2523/178,966 1.05 (0.96–1.15) 0.31
Diabetes-related
HbA1c 2693/192,506 0.96 (0.91–1.02) 0.23
Glucose 2522/178,796 0.87 (0.78–0.97) 0.011
Renal-related
Cystatin-C 2711/193,798 0.93 (0.89–0.97) 0.001
Creatinine 2711/193,712 1.01 (0.96–1.06) 0.70
Total protein 2519/178,800 0.94 (0.88–1.01) 0.11
Urea 2711/193,678 1.01 (0.95–1.08) 0.69
Phosphate 2523/178,664 1.17 (1.05–1.29) 0.003
Urate 2708/193,596 1.00 (0.94–1.05) 0.88
Creatinine (Urine) 2811/199,658 1.08 (0.94–1.24) 0.26
Microalbumin (Urine) 1040/74,624 1.00 (0.92–1.10) 0.95
Potassium/creatinine ratio (Urine) 2804/199,224 0.91 (0.77–1.07) 0.25
Sodium/creatinine ratio (Urine) 2808/199,472 0.86 (0.72–1.04) 0.12
Liver-related
Albumin 2524/179,025 1.06 (0.98–1.15) 0.14
Direct bilirubin 2517/180,458 0.99 (0.93–1.05) 0.80
Total bilirubin 2699/192,967 0.99 (0.94–1.05) 0.74
Gamma glutamyltransferase 2711/193,703 1.03 (0.98–1.09) 0.20
ALT 2711/193,651 1.03 (0.95–1.11) 0.52
AST 2702/193,023 0.91 (0.85–0.98) 0.013
Multivariable-adjusted hazard ratios (95% CI) for prostate cancer incidence excluding the first 4 years of follow-up and after correction for regression dilution
bias in UK Biobank. Cox regression analysis. HR are stratified by region and age at recruitment and adjusted for age (underlying time variable), Townsend
deprivation score, ethnicity, lives with a wife or partner, BMI, smoking, physical activity, alcohol consumption and diabetes. For vitamin D analyses, the model
was further adjusted for month of recruitment. Full details for each covariate are provided in the statistical section.
P values for trend from 1-SD higher concentrations analyses. Multivariable-adjusted P values marked in boldface were statistically significant after allowing for
multiple testing.
ALT alanine aminotransferase, AST aspartate aminotransferase, ApoA1 apolipoprotein A1, ApoB apolipoprotein B, BMI body mass index, CI confidence intervals,
HbA1c haemoglobin A1c, HDL high-density lipoprotein, HR hazard ratio, LDL-cholesterol low-density lipoperotein cholesterol, SD standard deviation.
Examination of potential novel biochemical factors in relation to. . .
A Perez-Cornago et al.
1815
Renal-related biomarkers
Although there are few prospective data on kidney disease and
prostate cancer risk, a previous individual patient data meta-
analysis found that men with kidney disease may have a lower
prostate cancer risk.9 Men with kidney disease are at higher risk of
having a very low circulating testosterone concentration,35 which
in turn has been associated with a lower prostate cancer risk.7
Findings from the present study showed that higher circulating
urea and phosphate concentrations were associated with an
increased prostate cancer risk, while cystatin-C and total protein
circulating concentrations (both markers of kidney function) were
associated with a lower risk. However, only the associations of
cystatin-C and phosphate with risk were significant in the last four
years of follow-up. These results may appear contradictory as all of
these are biomarkers of renal disease; however, these biomarkers
reflect different kidney functions. For example, elevated cystatin-C
is a marker of impaired glomerular filtration rate, while phosphate
concentrations are regulated by intestinal absorption, kidney
excretion and bone metabolism.36 To the best of our knowledge,
no previous prospective study has assessed the association of
circulating phosphate with prostate cancer risk; however, a
previous prospective study found a positive association between
phosphorous intake and risk of lethal prostate cancer risk37 and
there seems to be a positive association between the consump-
tion of foods with phosphate additives and higher circulating
concentrations.38 More studies are needed to clarify the associa-
tion between circulating phosphate concentrations and prostate
cancer risk.
Liver-related biomarkers
This study found that higher circulating concentrations of AST
were associated with a lower prostate cancer risk, although there
was no association after excluding the first 4 years of follow-up.
This is, to our knowledge, the first prospective study of the
association between these liver-related biomarkers and prostate
cancer risk and more studies with longer follow-up are needed to
further investigate this possible association. Only three previous
prospective studies have examined the association between non-
alcoholic fatty liver disease and prostate cancer risk, and the
results were inconsistent.39–41
Study strengths and limitations
To the best of our knowledge, this is the largest prospective study
looking at a wide range of biomarker measurements and prostate
cancer incidence and mortality data. The UK Biobank has
measured a panel of biomarkers in blood samples from the entire
cohort, including biomarkers that have not been previously
studied in prostate cancer analyses. Moreover, repeated measure-
ments of biomarkers were available for a subsample of repeat
blood specimens collected 4 years after recruitment, which has
made it possible for us to adjust estimates of associations between
biomarkers and risk for regression dilution bias.18 In addition, this
is a relatively young cohort, which permits examination of factors
related to earlier onset prostate cancer. Many covariates, such as
adiposity measurements or blood pressure, were assessed by
trained research clinic staff instead of being self-reported.
This study also has several limitations. Although UK Biobank
includes participants from multiple regions across the UK,
including deprived areas, it is not a representative sample of the
whole UK population11 and this cohort may have suffered from
selection bias,42 although the direction of risk factor associations
in the UK Biobank seem to be generalisable.43 As in every
observational study, there may be some residual confounding by
unmeasured risk factors. Some of the results may be influenced by
detection bias, as comorbidities may affect both biomarker
concentrations and prostate specific antigen test attendance
and/or results. Moreover, the blood samples of the current study
are non-fasting and we do not have 24-h urine samples, and
therefore, some biological measurements may have been affected
by time since last meal. While we performed sensitivity analyses
excluding the first 4 years of follow-up some of the associations
may be due to reversed causality, as the follow-up is relatively
short. Moreover, due to the small number of prostate cancer
deaths we had limited power to find associations. While we have
hypotheses for some of the biomarkers, we do not have a
hypothesis for others as they have not previously been assessed in
relation to prostate cancer, and some of the analyses using these
biomarkers were exploratory. Finally, as in other epidemiological
studies, there may be some misclassification of the underlying
cause of death; furthermore, information on tumour character-
istics, such as tumour stage and Gleason grade, is currently
unavailable in the UK Biobank.
In conclusion, we have reported a range of possible novel
biomarkers for prostate cancer incidence and mortality in this large
UK prospective study. Since some of these analyses were
exploratory, these results should be interpreted carefully. Future
analyses will include research by tumour characteristics, which will
help to determine whether these associations may be due to
differences in the likelihood of being diagnosed and/or differences
in the risk of developing clinically important prostate cancer.
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